Retrieve all available abstracts of the following 234 articles: HTML format
Single Articles
KONG L, Xu K, Bao X, Ye K, et al mTORC1 Selective Nano-Inhibitor by Disrupting the Lysosomal Arginine-SLC38A9-
mTORC1-CDKs Axis for Precision Bladder Cancer Therapy.
Adv Mater. 2025 Jul 4:e2504798. doi: 10.1002/adma.202504798. PubMed Abstract available
HUANG H, Hao H, Du J, Pang L, et al A nomogram for predicting overall survival in patients with muscle-invasive
bladder cancer undergoing radical cystectomy: a retrospective cohort study.
Front Oncol. 2025;15:1597107. PubMed Abstract available
MA X, Yao D, Yu W, Wu G, et al Comprehensive analysis of phagocytosis regulatory genes in bladder cancer:
implications for prognosis and immunotherapy.
Front Mol Biosci. 2025;12:1608519. PubMed Abstract available
KUROSU H, Yamada N, Nakamura R, Ito H, et al AEBP1-GLI1 pathway attenuates the FACT complex dependency of bladder cancer cell
survival.
Biochem Biophys Rep. 2025;43:102101. PubMed Abstract available
LEE JG, Petraccione J, Trese KA, Hughes AC, et al Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local
Adhesion and Drug Release to Bladder Cancers.
Adv Mater. 2025 Jul 4:e2505231. doi: 10.1002/adma.202505231. PubMed Abstract available
YANG WF, Guo WM, Luo QT, Lu J, et al Transcription factor TCF3 promotes bladder cancer development via
TMBIM6-Ca(2+)-dependent ferroptosis.
Cell Death Discov. 2025;11:303. PubMed Abstract available
SINYAGOVSKAYA T, Li Y, Vinchevskaya-Khmelnitskaya N, Agabalaeva A, et al The Role of m(6)A-RNA Methylation in the Development, Progression, and Treatment
Response of Bladder Cancer.
Biochemistry (Mosc). 2025;90:650-670. PubMed Abstract available
GUAN B, Zhang J, Chen S, Wang G, et al Long-term impact of synchronous and metachronous bladder cancer on prognosis
after radical nephroureterectomy for upper urinary tract urothelial carcinoma:
results from a large population-based cohort in China.
Int J Surg. 2025 Jul 3. doi: 10.1097/JS9.0000000000002892. PubMed Abstract available
TSUMORI T, Hoshi S, Yaginuma K, Meguro S, et al Combination of Neoadjuvant Gemcitabine-Cisplatin and Anti-Tuberculosis Therapy
for a Patient With Muscle-Invasive Bladder Cancer and Renal Granulomatosis That
Progressed After Intravesical Bacillus Calmette-Guerin Therapy.
IJU Case Rep. 2025;8:419-422. PubMed Abstract available
BERNARDO C, Chattopadhyay S, Andersson N, Eriksson P, et al Bladder cancer subtypes exhibit limited plasticity across different
microenvironments and in metastases.
Exp Hematol Oncol. 2025;14:91. PubMed Abstract available
LIU M, Zhang J, Zhang T, Zheng Q, et al Nordihydroguaiaretic acid inhibits bladder cancer metastasis through suppression
of alpha1,3-mannosyltransferase expression and LRFN4 N-glycosylation.
J Transl Med. 2025;23:733. PubMed Abstract available
LIU J, Lai S, Lu N, Luo S, et al The impact of surgery and survival prediction in patients with bladder
neuroendocrine carcinoma: a novel propensity score-matched population-based
cohort study.
Eur J Med Res. 2025;30:564. PubMed Abstract available
WANG T, Du A, Peng Y, Yin J, et al DSG3 promotes bladder cancer growth and metastasis via AKT/GSK3beta/beta-catenin
pathway.
J Transl Med. 2025;23:729. PubMed Abstract available
ST-LAURENT MP, Black PC Promise without practice - charting the path forward for bladder cancer
biomarkers.
Nat Rev Urol. 2025 Jul 2. doi: 10.1038/s41585-025-01064. PubMed
EL-HEFNAWY NE, Youssef MM, Abol-Enein H, Gabal RA, et al mTOR pathway targeted inhibition via Rapamycin-loaded PLGA nanoparticles for
enhanced bladder cancer therapy.
Sci Rep. 2025;15:23138. PubMed Abstract available
LIN YC, Chu CY, Hsieh TH, Lin BJ, et al FGFR inhibitors promote the autophagic degradation of IFN-gamma-induced PD-L1 and
alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in
non-muscle-invasive bladder cancer.
Cell Death Dis. 2025;16:485. PubMed Abstract available
NEDJADI T, Ansari H, Khan MA, Sannan N, et al Clinical relevance of the somatic mutational landscaping in predicting outcome of
bladder cancer patients.
Sci Rep. 2025;15:23292. PubMed Abstract available
BAGCI U, Ulusan Bagci O The bibliometric analysis of documents concerning the relationship between the
microbiota and urological malignancies.
J Med Microbiol. 2025;74:002041. PubMed Abstract available
YANG Z, Liu Y, Li J, Wang X, et al Toripalimab treatment of bladder-preserving therapy for locally advanced bladder
cancer: a case report.
Front Oncol. 2025;15:1581452. PubMed Abstract available
HUANG D, Guo N, Peng Y, Nie Z, et al Long-term resident adipose-derived stromal stem cells in the microenvironment
remodeling BLCA cell stemness and EMT promotes bladder cancer progression.
Sci Rep. 2025;15:23049. PubMed Abstract available
ZENNAMI K, Nukaya T, Ishikawa K, Tomozawa S, et al Exposure to ileal feces with frailty-associated dysbiosis elevates
gastrointestinal complication risk after intracorporeal urinary diversion.
Sci Rep. 2025;15:22333. PubMed Abstract available
CHEN X, Guo H, Cao S, Lin J, et al Disease burden of bladder cancer in China and the different SDI regions over the
world from 1990 to 2021.
Sci Rep. 2025;15:20811. PubMed Abstract available
LEE S, Lim B, Suh J, Hong B, et al Diagnostic accuracy of urinary PENK methylation test for urothelial and other
cancers: A prospective study.
Sci Rep. 2025;15:22149. PubMed Abstract available
DEY S, Pattanaik S, Kakkar N, Konar M, et al Expression of ALDH1 isotypes and its potential as a prognostic and diagnostic
marker in patients with muscle invasive bladder cancer.
Sci Rep. 2025;15:22599. PubMed Abstract available
HSIEH TH, Kuo HP, Chen MC, Lin YC, et al Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with
chemotherapeutic agents in cisplatin resistant bladder cancer cells.
Sci Rep. 2025;15:20922. PubMed Abstract available
ZHANG QJ, Liu CH, Wang K, Mao XY, et al Hypoxia-induced HIF-1alpha/VASN promotes bladder cancer progression.
Sci Rep. 2025;15:21635. PubMed Abstract available
ADOMI S, Sakai K, Kura Y, De Velasco MA, et al Comparison of genetic mutations in bladder cancers that arose following
radiotherapy for prostate cancer with those in primary bladder cancers.
Sci Rep. 2025;15:20495. PubMed Abstract available
LIU X, Yin X, Yuan F, Li S, et al PKIB facilitates bladder cancer proliferation and metastasis through mediation of
HSP27 phosphorylation by PKA.
Cell Death Dis. 2025;16:470. PubMed Abstract available
IYER G, Choi W, Luo B, Carvalho F, et al Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and
Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB
90601.
JCO Precis Oncol. 2025;9:e2400938. PubMed Abstract available
ABDLKADIR AS, Al-Adhami D, Allouzi S, Badarneh M, et al Diagnostic efficacy of [(18)F]FDG PET/CT and [(18)F]FDG PET/MRI in preoperative
staging of locoregional urinary bladder cancer: a systematic review and
Meta-Analysis.
Discov Oncol. 2025;16:1241. PubMed Abstract available
HE W, Xie J, Wang Z, Wang M, et al Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder
cancer.
Discov Oncol. 2025;16:1197. PubMed Abstract available
TAN Z, Chen X, Fu S, Huang Y, et al Machine Learning and Experimental Validation Reveal MYH11 as a Novel Prognostic
Biomarker and Therapeutic Target in Bladder Cancer.
J Inflamm Res. 2025;18:8357-8387. PubMed Abstract available
STEINER L, Eldh M, Offens A, Veerman RE, et al Corrigendum to "Protein profile in urinary extracellular vesicles is a marker of
malignancy and correlates with muscle invasiveness in urinary bladder cancer"
[Cancer Lett 609 (2025) 217352].
Cancer Lett. 2025 Jun 29:217876. doi: 10.1016/j.canlet.2025.217876. PubMed
DE ANGELIS M, Siech C, Di Bello F, Penaranda NR, et al The effect of race/ethnicity on systemic chemotherapy in urothelial carcinoma
patients exposed to radiotherapy.
World J Urol. 2025;43:403. PubMed Abstract available
CAI Q, Tian L, Kong L, Zhang K, et al Multiparametric MRI for assessing residual tumors in patients with
muscle-invasive bladder cancer after neoadjuvant treatment: a reliable tool for
guiding bladder preservation.
Eur Radiol. 2025 Jun 30. doi: 10.1007/s00330-025-11773. PubMed Abstract available
FAN L, Xu F, Liu S, Wu D, et al NR4A3 suppresses bladder cancer progression by modulating autophagy via the
PI3K/AKT/mTOR pathway.
Eur J Histochem. 2025;69. PubMed Abstract available
MUSONE M, Chianese S, Chervino C, Madonna A, et al Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving
horizon.
J Basic Clin Physiol Pharmacol. 2025 Jul 1. doi: 10.1515/jbcpp-2025-0106. PubMed
GOEL V, Jain A, Basu DA, Patnaik N, et al A Comparative Study of Gemcitabine-Cisplatin vs. Dose-Dense MVAC (Methotrexate,
Vinblastine, Doxorubicin, and Cisplatin) as Neoadjuvant Chemotherapy for
Muscle-Invasive Bladder Cancer: A Single-Institution Experience.
Cureus. 2025;17:e85071. PubMed Abstract available
GURBANI CM, Chong YL, Choo ZW, Chia D, et al Emerging bladder-sparing treatments for high risk non-muscle invasive bladder
cancer.
Bladder Cancer. 2025;11:23523735251348842. PubMed Abstract available
CHEN Y, Tong E, Rao Y, Yu EY, et al The associations between sleep-related factors and bladder cancer: A
cross-sectional study in the UK Biobank.
Cancer Epidemiol. 2025;97:102871. PubMed Abstract available
SOUZA AP, Silva IM, Vacario BGL, Koike A, et al The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide
metabolites, protecting urothelial bladder cancer patients from recurrence.
Mol Biol Rep. 2025;52:649. PubMed Abstract available
KRUPA S, Szuberla W, Niziol J, Ossolinska A, et al Broadband Collision-Induced Dissociation Mass Spectrometry Imaging.
J Am Soc Mass Spectrom. 2025;36:1443-1455. PubMed Abstract available
GERSHMAN B, Ernandez J, Kaul S, Perez-Londono A, et al Comprehensive characterization of the real-world perioperative morbidity of
radical cystectomy in older adults.
J Geriatr Oncol. 2025;16:102265. PubMed Abstract available
SRIDALLA K, Patel HD, French DD, Meeks JJ, et al Evaluating Cost-Effective Strategies for Asymptomatic Microhematuria Diagnosis: A
Risk-Based Alternative to the American Urological Association Guidelines.
J Surg Oncol. 2025;131:1661-1669. PubMed Abstract available
GIBBS NH, Sola MF, Dhawan D, Knapp D, et al Hypoxia-inducible factor 1alpha expression does not differ between canine urothelial
carcinoma and normal urinary bladder tissue.
Am J Vet Res. 2025;86:ajvr. PubMed Abstract available
MONSONIS-USO R, Ponce-Blasco P, Amaya-Barroso B, Martinez-Meneu P, et al Identification of risk factors for evisceration in open radical cystectomy.
Actas Urol Esp (Engl Ed). 2025;49:501759. PubMed Abstract available
DI BELLO F, Rodriguez Penaranda N, Marmiroli A, Longoni M, et al Robot-Assisted Versus Open Radical Cystectomy: Comparison of Adverse In-Hospital
Outcomes.
J Surg Oncol. 2025;131:1651-1660. PubMed Abstract available
HEIDENREICH A, Bohmer D, Bolenz C, Borkowetz A, et al New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder.
Dtsch Arztebl Int. 2025;122:211-218. PubMed Abstract available
KUMAR P, Ruhl J, Chiddarwar TV, Garibay-Trevino DU, et al Long-term trends in bladder cancer incidence using a harmonized staging variable
- A SEER-based study.
Cancer Epidemiol Biomarkers Prev. 2025. PubMed Abstract available
NARGIS N, Lind A, Sczepanski A, Herndon R, et al SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy
Response in Urothelial Carcinoma.
Cells. 2025;14:949. PubMed Abstract available
MOSTAFAEI H, Salehi-Pourmehr H, Sadeghi Ghyassi F, Mostafaei H, et al An evidence gap map of the personalized medicine in bladder cancer.
Per Med. 2025 Jul 11:1-10. doi: 10.1080/17410541.2025.2530918. PubMed Abstract available
DU K, Kang N, Lin Y, Jia K, et al Senescence-associated signature based on immunotherapy response sequencing
reveals PPIL3 as target for bladder cancer treatment and prognosis prediction.
Front Immunol. 2025;16:1613056. PubMed Abstract available
STRASENBURG W, Borowczak J, Piatkowska D, Jozwicki J, et al The role of DNA methylation and demethylation in bladder cancer: a focus on
therapeutic strategies.
Front Oncol. 2025;15:1567242. PubMed Abstract available
HU H, Liu B Urogenital Function and Oncologic Outcomes after Nerve-Sparing Radical
Cystectomy: A Systematic Review and Meta-Analysis.
Arch Esp Urol. 2025;78:604-612. PubMed Abstract available
HU B, Wang L, Qu S, Zhang T, et al Construction of a column-line graphical model of poor outcome of neoadjuvant
regimens for muscle-invasive bladder cancer based on NLR, dNLR and SII
indicators.
World J Surg Oncol. 2025;23:274. PubMed Abstract available
HE N, Bao LR, Ma PC, Fu ZL, et al MSH6 as a prognostic biomarker in bladder cancer and its correlation with
immunity.
Sci Rep. 2025;15:24837. PubMed Abstract available
CHEN H, Jin Z, Peng Y, Li Y, et al Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1+ macrophage confers
resistance to neoadjuvant immunotherapy in bladder cancer.
J Immunother Cancer. 2025;13:e011319. PubMed Abstract available
JI J, Lai CH, Lai S, Wang M, et al Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among
Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study.
Ann Surg Oncol. 2025 Jul 10. doi: 10.1245/s10434-025-17654. PubMed Abstract available
SMANI S, Lokeshwar SD, Jalfon M, Heckscher D, et al Development and Utilization of a Novel EHR-Based Care Pathway for Non-muscle
Invasive Bladder Cancer.
Urol Pract. 2025 Jul 10:101097UPJ0000000000000872. PubMed Abstract available
GOTTO G, Alimohamed NS, Kulkarni GS, Black PC, et al A population-based analysis of patterns of care in patients with high-risk
non-muscle-invasive bladder cancer from Alberta, Canada.
Can Urol Assoc J. 2025 Jul 8. doi: 10.5489/cuaj.9110. PubMed Abstract available
FU ZQ, Sun N, An L A case of rapidly progressive fatal pulmonary hypertension in a patient with
metastatic bladder cancer: reflections on the early recognition of pulmonary
tumour thrombotic microangiopathy.
J Geriatr Cardiol. 2025;22:596-599. PubMed
MOHANASUNDARAM A, Raja V, Kamalakannan Y, Islam MA, et al Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.
Adv Pharm Bull. 2025;15:4-6. PubMed
LIU Z, Chen C, Yin J, Cong X, et al Changing landscape of first-line treatment for locally advanced or metastatic
urothelial carcinoma: the progression from platinum-based chemotherapy to
platinum-free therapy.
Front Immunol. 2025;16:1604395. PubMed Abstract available
LI S, Yang K, Jin Z, Yan P, et al Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of
emerging therapeutic targets.
iScience. 2025;28:112720. PubMed Abstract available
ZHANG L, Wang Y, Tan J Analysis of Single-Cell RNA-Seq Data to Investigate Tumor Cell Heterogeneity in
Uroepithelial Bladder Cancer and Predict Immunotherapy Response.
Curr Cancer Drug Targets. 2025 Jul 8. doi: 10.2174/0115680096377593250626133719. PubMed Abstract available
HAYASHI T, Kawashima A, Ujike T, Takao T, et al Preoperative CRP is a predictive factor for prolonged hospital stay after radical
cystectomy for bladder cancer.
BMC Urol. 2025;25:162. PubMed Abstract available
PAN J, Zheng GF, Rui X Correspondence on "METTL3 promotes an immunosuppressive microenvironment in
bladder cancer via m6A-dependent CXCL5/CCL5 regulation" by Tong et al.
J Immunother Cancer. 2025;13:e012565. PubMed
XU L, Lin Y, Zhang L, Lin X, et al Long non-coding RNA MINCR silencing contributes to suppressed gemcitabine
resistance in bladder cancer by blocking the ZEB1/PHGDH axis through
microRNA-876-5p up-regulation.
J Mol Histol. 2025;56:220. PubMed Abstract available
YUDOVICH MS, Alzubaidi AN, Raman JD Response to Comment on "Artificial Intelligence Can Facilitate Application of
Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios".
Clin Med Insights Oncol. 2025;19:11795549251350233. PubMed
DAUNGSUPAWONG H, Wiwanitkit V Comment on: "Artificial Intelligence Can Facilitate Application of Risk
Stratification Algorithms to Bladder Cancer Patient Case Scenarios".
Clin Med Insights Oncol. 2025;19:11795549251350242. PubMed
YU C, Chu N, Aguirre A, Green J, et al Intrinsic higher potency of basal urothelial cells to intermediate and umbrella
cells as the cell of origin for bladder cancer.
bioRxiv [Preprint]. 2025 Jul 3:2025.06.28.662140. doi: 10.1101/2025.06.28.662140 PubMed Abstract available
LIANG Z, Nong F, Li Z, Chen R, et al Taurine-mediated metabolic immune crosstalk indicates and promotes
immunosuppression with anti-PD-1 resistance in bladder cancer.
Front Immunol. 2025;16:1618439. PubMed Abstract available
DENG H, Huang J, Gao N, Liu Z, et al Nanotherapeutic System with Effective Microwave Sensitization and Pyroptosis
Programming Enable Synergistic Microwave-Immunotherapy in Bladder Cancer.
Biomater Res. 2024;28:0077. PubMed Abstract available
NING W, Yang YR, Wu CX, Hou Y, et al CHMP6 as a novel prognostic biomarker in bladder cancer: insights from a
comprehensive cell death-related gene risk model.
Front Oncol. 2025;15:1564826. PubMed Abstract available
WU J, Zong D, Li F Enhanced photodynamic therapy with riboflavin@ dual minerals doped hydroxyapatite
nanoparticles: A promising in vitro approach for bladder cancer.
J Photochem Photobiol B. 2025;270:113207. PubMed Abstract available
RIZZO M, Soares A, Gupta S, Calabro F, et al Geographical Differences in the Management and Outcomes of Patients With Advanced
Urothelial Carcinoma Treated With Pembrolizumab After Progression on
Platinum-Based Chemotherapy: Results From ARON-2 Study.
JCO Glob Oncol. 2025;11:e2400564. PubMed Abstract available
VIEHWEGER F, Gorbokon N, Buyucek S, Plage H, et al KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas
of the urinary bladder.
Pathologica. 2025;117:296-305. PubMed Abstract available
LEE J, Choi S, Kwon GY Invasiveness or growth pattern in urothelial tumours. A perspective to rethink
the current WHO classification.
Pathologica. 2025;117:243-248. PubMed Abstract available
ZHANG J, Fan X, Xu X, Han Y, et al Epigenetic dysregulation-induced metabolic reprogramming fuels tumor progression
in bladder cancer.
Front Mol Biosci. 2025;12:1602700. PubMed Abstract available
BIRD L BCG plus beta-glucan trains neutrophils to beat bladder cancer.
Nat Rev Immunol. 2025 Jul 7. doi: 10.1038/s41577-025-01209. PubMed
ALQASEM S, Wojcik S, Corcos J From immunotherapy to autoimmunity: reactive arthritis following intravesical
BCG.
BMJ Case Rep. 2025;18:e267448. PubMed Abstract available
CARRENO GL, Fu H, Messer J Comparison of perioperative outcomes between Bricker and Wallace anastomosis
techniques in robotic-assisted radical cystectomy with intracorporeal diversion.
World J Urol. 2025;43:415. PubMed Abstract available
BARDOWSKA K, Krajewski W, Kolodziej A, Koscielska-Kasprzak K, et al Preoperative systemic inflammatory biomarkers can improve recurrence prediction
of non-muscle invasive bladder cancer after endoscopic resection - a prospective
observational study.
Contemp Oncol (Pozn). 2025;29:188-194. PubMed Abstract available
CHENG TY, Chiu YC, Chen KH, Chen YJ, et al Galactosylated silver nanoparticles as a biocompatible intrinsic SERS probe for
bladder cancer imaging and ex vivo tumor detection.
J Mater Chem B. 2025 Jul 7. doi: 10.1039/d5tb00546. PubMed Abstract available
CHO S, Chung HS, Jung SI, Lim DG, et al The role of Uro-Vaxom in reducing infectious adverse effects and improving
outcomes in bacillus Calmette-Guerin therapy for non-muscle-invasive bladder
cancer.
Investig Clin Urol. 2025;66:344-351. PubMed Abstract available
SHIMIZU F, Muto S, Kitamura K, Kimura T, et al Totally intracorporeal ileal neobladder following robot-assisted radical
cystectomy in male patients using the Juntendo technique: Initial experience.
Investig Clin Urol. 2025;66:320-328. PubMed Abstract available
KIM JS, Lee J, Lee CU, Nguyen TT, et al Impact of regular cystoscopy on prognosis in non-muscle-invasive bladder cancer:
A nationwide study.
Investig Clin Urol. 2025;66:302-310. PubMed Abstract available
ULUS I, Ozsoy S, Cin S, Yilmaz M, et al Predictive value of tumor invasion patterns on intravesical bacillus
Calmette-Guerin response for stage T1 high-grade non-muscle-invasive bladder
cancer.
Investig Clin Urol. 2025;66:295-301. PubMed Abstract available
WALLACE BK, Su ZT, Flynn JP, Garman TS, et al National trends in diagnoses of subtype histologies in bladder cancer: A
population-based study based on the SEER database.
Urol Oncol. 2025 Jul 4:S1078-1439(25)00239-X. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
LI J, Chen Q, Wang J, Wang Z, et al Causal Role of Phenylalanine and Cholesterol Metabolism in Bladder Cancer
Chemoresistance: Insights from Mendelian Randomization and Targeted Molecular
Docking.
Arch Biochem Biophys. 2025 Jul 3:110530. doi: 10.1016/j.abb.2025.110530. PubMed Abstract available
NICOLAZZINI M, Longoni M, Falkenbach F, Marmiroli A, et al Extracorporeal vs. intracorporeal urinary diversion at robot-assisted radical
cystectomy: adverse in-hospital outcomes.
J Robot Surg. 2025;19:351. PubMed Abstract available
PERIASAMY K, Goyal S, Kumar S, Chandran V, et al Extended field chemoradiation in M1a bladder carcinoma: A case report.
J Cancer Res Ther. 2025;21:725-729. PubMed Abstract available
HUANG W, Xu Y, Liu J, Cheng T, et al Identification and single-cell analysis of prognostic genes related to
mitochondrial and neutrophil extracellular traps in bladder cancer.
Sci Rep. 2025;15:23982. PubMed Abstract available
SCHARP D, Leung TM, Jensen BT, Lauridsen SV, et al Age-related differences in unmet needs and their predictors among adults with
bladder cancer.
Urol Oncol. 2025 Jul 3:S1078-1439(25)00241-8. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
BRUCK K, Atema V, Leliveld AM, Franckena M, et al Health-related quality of life in patients treated for non-metastatic
muscle-invasive bladder cancer: radical cystectomy versus bladder preserving
therapy.
Int J Radiat Oncol Biol Phys. 2025 Jul 2:S0360-3016(25)04509. PubMed Abstract available
CHRONOPOULOS J, Crespo M, Chavakis T Central trained immunity in the context of bladder cancer immunotherapy.
Cancer Cell. 2025 Jun 27:S1535-6108(25)00260-0. doi: 10.1016/j.ccell.2025. PubMed Abstract available
ZHENG L, Cao J, Ma L, Chen S, et al LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered
Cancers.
J Med Chem. 2025;68:13858-13871. PubMed Abstract available
GUO H, Jin B, Zhu Z, Dai X, et al Nanoparticle-Protein Corona Boosted Cancer Diagnosis with Proteomic Transfer
Learning.
ACS Nano. 2025;19:23592-23605. PubMed Abstract available
AYTEN A, Eksi M, Civan O, Colakoglu Y, et al Prospective Evaluation of the Effect of Vesical Imaging Reporting and Data System
Scoring on the Identification of Candidates for Repeated Transurethral Resection.
J Laparoendosc Adv Surg Tech A. 2025;35:557-563. PubMed Abstract available
ZHANG Q, Du Y, Wang D, Du G, et al Postoperative continuous saline bladder irrigation reduces active urinary cancer
cells: a prospective study in NMIBC.
Cell Oncol (Dordr). 2025;48:991-1003. PubMed Abstract available
CHIDDARWAR TV, Jalal H, Alarid-Escudero F, Garibay D, et al Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line
Metastatic Urothelial Cancer in the United States.
Value Health. 2025;28:1009-1017. PubMed Abstract available
MINATO A, Takaba T, Sugita Y, Kaneko Y, et al Clinical significance of the dose modification of enfortumab vedotin monotherapy
for advanced urothelial carcinoma.
Jpn J Clin Oncol. 2025;55:791-796. PubMed Abstract available
NG CPY, Light A, Eleftheriou C, Hug O, et al Long-term outcome of transurethral laser ablation for recurrent non-muscle
invasive bladder cancer: An EORTC risk-matched study.
BJUI Compass. 2025;6:e70052. PubMed Abstract available
LIU S, Zhang J, Wang X Case Report: A patient with metastatic bladder cancer in the stomach.
Front Oncol. 2025;15:1591475. PubMed Abstract available
WEN D, Fu P, Shuai G, Wang Y, et al The impact of METTL3 on bladder cancer through m(6)A modification: a potential
therapeutic target and prognostic biomarker.
Front Oncol. 2025;15:1622117. PubMed Abstract available
LEE DH, Yoo JK, Um KH, Ha W, et al Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder
cancer treatment.
J Exp Clin Cancer Res. 2025;44:210. PubMed
ERRATUM FOR CYSTECTOMY IN METASTATIC BLADDER CANCER: FEASIBILITY, SAFETY AND
OUTCOMES PUBLISHED IN EXP ONCOL 2024;46(4).
Exp Oncol. 2025;47:124. PubMed Abstract available
ZHANG H, Yan M, Zhang J, Sun P, et al [Pirfenidone inhibits bladder cancer xenograft growth in mice by regulating
regulatory T cells].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:1513-1518. PubMed Abstract available
AMPARO TR, Anunciacao KFD, Almeida TC, Silva GND, et al Beta-Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and
lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles.
Drug Dev Res. 2025;86:e70128. PubMed Abstract available
GUSKE C, Jazayeri SB, Harrs C, Rao N, et al Assessing the Impact of Treatment Timing Protocols in Clinical Trials for
Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Jul 15:S2588-9311(25)00164. PubMed Abstract available
KRAFT P, Schregel C, Obrecht F, Foerster B, et al Reinforcing expectations after robot-assisted intracorporeal orthotopic
neobladder: long-term functional, urodynamic and metabolic outcome.
World J Urol. 2025;43:437. PubMed Abstract available
NALLY E, Powles T Perioperative durvalumab for muscle invasive bladder cancer: the start of a new
chapter.
Future Oncol. 2025 Jul 16:1-3. doi: 10.1080/14796694.2025.2531574. PubMed
MA M, Li J, Li X, Jing M, et al Piezo1/ITGB1 Synergizes With Ca(2+)/YAP Signaling to Propel Bladder Carcinoma
Progression via a Stiffness-Dependent Positive Feedback Loop.
Cancer Med. 2025;14:e71059. PubMed Abstract available
SHEN C, Liu J, Hu D, Liu C, et al Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and
facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer.
J Exp Clin Cancer Res. 2025;44:207. PubMed Abstract available
LIU Q, Wang J, Gao S, Li Z, et al ERalpha-dependent crosstalk between macrophages and cancer cells potentiates
vasculogenic mimicry and M2 macrophage polarization in bladder cancer.
Cell Commun Signal. 2025;23:339. PubMed Abstract available
MARKO V, Petar K, Aleksandar M, Marko A, et al Posterior conduit fixation with retroperitonealization of uretero-ileal
anastomosis after open radical cystectomy reduces the postoperative complication
rate: a retrospective, matched-paired single-center analysis.
BMC Urol. 2025;25:173. PubMed Abstract available
LI Y, Zuo L, Song X, Huang Y, et al Developing angiogenesis-related prognostic biomarkers and therapeutic strategies
in bladder cancer using deep learning and machine learning.
Sci Rep. 2025;15:25534. PubMed Abstract available
WANG S, Cheng J, Hu Z, Zhao H, et al Bioinformatics analysis of COMMD family in pan-cancer reveals potential
biomarkers and therapeutic targets.
Sci Rep. 2025;15:25490. PubMed Abstract available
GORBOKON N, Teljuk K, Reiswich V, Lutz F, et al MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial
carcinoma of the urinary bladder.
Sci Rep. 2025;15:25581. PubMed Abstract available
KUBIK A, das Virgens IPA, Varga N, Szabo A, et al Radical Surgery Compared to Bladder-Preserving Approaches for Limited Stage
Small-Cell Bladder Cancer: Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2025 Jun 22:102389. doi: 10.1016/j.clgc.2025.102389. PubMed Abstract available
HOLMSTEN K, De Laere B, Sjodahl G, Lindberg J, et al Exploring novel genomic biomarkers for response and survival after neoadjuvant
chemotherapy and radical cystectomy of muscle-invasive bladder cancer.
ESMO Open. 2025;10:105512. PubMed Abstract available
GUAN L, Zheng F, Li S, Yuan Y, et al Myeloid cell differentiation-related gene signature predicts the prognosis and
immunotherapy response in bladder cancer.
Comput Methods Biomech Biomed Engin. 2025. PubMed Abstract available
ZHANG F, Li S, Zhang Z, Li J, et al Identification of DNA Replication Stress-Related Genes as Prognostic Biomarkers
for Bladder Cancer.
Comb Chem High Throughput Screen. 2025. PubMed Abstract available
CHEN X, Huang M, Chen Z, Zhang C, et al Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk
Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial
Study.
MedComm (2020). 2025;6:e70288. PubMed Abstract available
SONG R, Chen X, Zhang Z, Wang H, et al CENPF overexpression in bladder cancer cells enhances proliferation, migration,
invasion, and apoptosis.
Sci Rep. 2025;15:25398. PubMed Abstract available
BADR EAE, Mekhail Y, Hassan KSA, Assar MFA, et al The role of SHMT2 and NDUFA4L2 gene expression and UCA1 levels in Egyptian
patients with bladder cancer.
J Immunoassay Immunochem. 2025 Jul 14:1-15. doi: 10.1080/15321819.2025.2533800. PubMed Abstract available
ZHANG H, Zhang X, Du Y, Xiong W, et al High FSTL1 expression promotes bladder cancer progression by enhancing tumor cell
migration.
Clin Transl Oncol. 2025 Jul 14. doi: 10.1007/s12094-025-03964. PubMed Abstract available
BHATTACHARYA U, Toppo SK, Xalxo AR, Ranjan RK, et al Role of 256 and 128 Slice Multidetector Computed Tomography Scan (MDCT) in the
Staging of Urinary Bladder Cancer with its Histopathological Correlation.
J Pharm Bioallied Sci. 2025;17. PubMed Abstract available
CAO J, Wang G, Zhao Y, Zhang G, et al Protein Tyrosine Kinase 2 Circular RNA Promotes Proliferation and Invasion of
Bladder Cancer.
Cell Physiol Biochem. 2025;59:453-464. PubMed Abstract available
HATAKEYAMA S, Fujita N, Kobayashi M, Kandori S, et al Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive
urothelial carcinoma.
Sci Rep. 2025;15:25247. PubMed Abstract available
XIONG Y, Dong Q, Hu H, Li Z, et al Glucose-induced STUB1-GOT2 axis promotes aspartate synthesis and mitochondrial
dysfunction in bladder cancer.
Cell Death Dis. 2025;16:516. PubMed Abstract available
TASIOS A, Amstutz U, Seiler R, Fuhlbruck F, et al In Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy,
Dynamics of Circulating Tumor DNA Following Cystectomy: Association with Patient
Outcomes.
Eur Urol Focus. 2025 Jul 11:S2405-4569(25)00184. PubMed Abstract available
ZHANG Y, Zhang H, Li Y, Ma X, et al Disease burden and trends of bladder cancer in the world and BRICS from 1990 to
2021 and its projection until 2036: analysis based on the global burden of
disease study 2021.
Discov Oncol. 2025;16:1319. PubMed Abstract available
CHUNG CM, Chang H, Chang CH, Chang YH, et al Integrative Analysis of GATA3 Expression and Variants as Prognostic Biomarkers in
Urothelial Cancer.
Int J Mol Sci. 2025;26:6378. PubMed Abstract available
KASPERCZYK E, Tarhonska K, Jablonska E Genotoxicity Induced by Carcinogenic Agents or Occupational Exposure with
Sufficient Evidence for Bladder Cancer.
J Clin Med. 2025;14:4492. PubMed Abstract available
PARK JH, Hong JY, Han K, Shen JJ, et al Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer
Risk: A Nationwide Cohort Study.
Cancers (Basel). 2025;17:2262. PubMed Abstract available
RODLER S, Ledderose ST, Waidelich R, Kohler J, et al Expression Profiles of Co-Inhibitory Receptors in Non-Urothelial Bladder Cancer:
Preclinical Evidence for the Next Generation of Immune Checkpoint Inhibitors.
Cancers (Basel). 2025;17:2210. PubMed Abstract available
BIZZARRI FP, Campetella M, Russo P, Palermo G, et al Prognostic Value of PLR, SIRI, PIV, SII, and NLR in Non-Muscle Invasive Bladder
Cancer: Can Inflammatory Factors Influence Pathogenesis and Outcomes?
Cancers (Basel). 2025;17:2189. PubMed Abstract available
EHRLICH MI, Fox RD, Runcie KD, Stein MN, et al Novel Strategies and Therapeutic Advances for Bladder Cancer.
Cancers (Basel). 2025;17:2070. PubMed Abstract available
WU F, Wu S, Huang Y, Xiao X, et al Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis.
J Transl Med. 2025;23:785. PubMed Abstract available
XIONG Y, Li Y, Chen L, Chen M, et al Enhancing the therapeutic efficacy of gemcitabine in bladder cancer through
TGF-beta1 inhibition and pluronic F-127-based microsphere delivery.
J Biol Eng. 2025;19:62. PubMed Abstract available
GUO L, An T Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative
Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol
Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008.
Eur Urol Focus. 2025 Jul 10:S2405-4569(25)00188. PubMed
TAN YJ, Ren YS, Lv JL, Zhao P, et al Cistanoside F acts as a Monoacylglycerol Lipase inhibitor that synergizes the
anti-tumor effect of 2-Arachidonoyl Glycerol on Bladder cancer.
Phytomedicine. 2025;145:157046. PubMed Abstract available
YE K, Bao X, Song Z, Zhang M, et al A mono-substituted aluminum phthalocyanine photosensitizer with high
phototoxicity index for effective bladder cancer treatment.
Bioorg Chem. 2025;163:108730. PubMed Abstract available
CHEN C, Tong M, Chang Y, Li X, et al Arsenic enhances endoplasmic reticulum stress via YTHDC1/AKR1C3 aix to promote
the malignant transformation of human urothelial cells.
Toxicol Lett. 2025;410:199-210. PubMed Abstract available
MATSUBARA N, Loriot Y, Burgess EF, Park SH, et al Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered
Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed
Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in
the THOR Phase 3
Clin Genitourin Cancer. 2025;23:102376. PubMed Abstract available
PANG X, Jiang L, Wang H, Luo L, et al Impact of Muscle Depletion on Prognosis in Patients Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2025;23:102373. PubMed Abstract available
ZHU H, Xiao Q, Zhang H, Zhou M, et al Risk assessment for the bladder carcinogenesis of 4-aminobiphenyl in smokers: A
source-to-outcome study.
Toxicol Lett. 2025;410:23-31. PubMed Abstract available
RAJA KD, Singh A, Akhtar S, Singh P, et al Phenotypic Diversity of Immunosuppressive B Cells Associated in Urothelial
Carcinoma of the Bladder.
Clin Genitourin Cancer. 2025;23:102351. PubMed Abstract available
ANCESCHI U, Di Maida F, Chiacchio G, Mastroianni R, et al A Novel Scoring System to Assess Continence Quality Outcomes of Orthotopic Ileal
Neobladders After Open and Robot-Assisted Radical Cystectomy: The Urodynamic
Trifecta.
Neurourol Urodyn. 2025;44:1255-1263. PubMed Abstract available
BAKALOUDI DR, Talukder R, Enright T, Leary JB, et al Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced
Urothelial Carcinoma and Histology Subtypes.
Clin Genitourin Cancer. 2025;23:102356. PubMed Abstract available
YIN L, Han X, Guo F, Zou Y, et al An All-in-One Nanohole Array for Size-Exclusive Trapping and High-Throughput
Digital Counting of Single Extracellular Vesicles for Non-Invasive Cancer
Screening.
Angew Chem Int Ed Engl. 2025;64:e202506744. PubMed Abstract available
KARABURUN MC, Serbes ED, Akpinar C, Obaid K, et al Assessment of the Impact of Grade Heterogeneity on Survival in Ta and T1 Tumors:
A Subgroup Analysis of NMIBC Cohort.
Clin Genitourin Cancer. 2025;23:102357. PubMed Abstract available
KOIKE Y, Urabe F, Muramoto K, Goto Y, et al Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy
for Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2025;23:102354. PubMed Abstract available
MA ML, Zhang WZ, Jiang P, Ji L, et al Chromatin accessibility states affect transrenal clearance of plasma DNA:
Implications for urine-based diagnostics.
Med. 2025;6:100646. PubMed Abstract available
REGELE E, Beran K, Hanchate K, Hochwald A, et al Prophylactic heparin does not increase clinically significant bleeding following
transurethral resection of a bladder tumor.
Urol Oncol. 2025;43:469. PubMed Abstract available
LEE RS, Zahir M, Douglawi A, Ladi-Seyedian SS, et al The association between perioperative activity levels and discharge outcomes
after radical cystectomy.
Urol Oncol. 2025;43:468. PubMed Abstract available
PELAEZ I, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, et al Clinical advances and practice updates in genitourinary cancers: a 2024 review
from the multidisciplinary Spanish 'Cambados annual meeting'.
Clin Transl Oncol. 2025;27:3307-3324. PubMed Abstract available
MOCHIZUKI F, Hanazawa M, Komine M, Sunabe H, et al Concomitant Interstitial Pneumonia and Disseminated BCG Infection after
Intravesical BCG Therapy.
Intern Med. 2025;64:2218-2222. PubMed Abstract available
GRIMAUD LW, Schroeder TE, Martinez M, Sury K, et al Post-radiation simple cystectomy for end-stage bladder in cancer survivors is not
associated with occult malignancy.
World J Urol. 2025;43:455. PubMed Abstract available
COSKUN A, Sahin AB, Kabul S, Celik MA, et al Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary
Bladder: A Propensity Score-Matched Analysis.
Curr Oncol. 2025;32:394. PubMed Abstract available
GILBERT SM What Is the Optimal Perioperative Treatment for Variant Subtypes of Bladder
Cancer?
Eur Urol Focus. 2025 Jul 23:S2405-4569(25)00206. PubMed Abstract available
LEE T, MacDonald L, Lawen T, Kamat AM, et al Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what's new in
2025?
Expert Rev Anticancer Ther. 2025 Jul 24. doi: 10.1080/14737140.2025.2535657. PubMed Abstract available
MOREIRA IB, Rossdam C, Kaynert J, Beimdiek J, et al Neolactotetraosylceramide enables urinary detection of bladder cancer.
Cell Rep Med. 2025 Jul 18:102246. doi: 10.1016/j.xcrm.2025.102246. PubMed Abstract available
EMRICH G 2025 ASCO Bladder Cancer Highlights.
Oncol Res Treat. 2025 Jul 24:1-6. doi: 10.1159/000547631. PubMed Abstract available
CHEN T, Huang C, Liu Y, Nie D, et al Bimetallic nanozyme-mediated dual ferroptosis/cuproptosis synergy potentiates
immunotherapy in bladder cancer.
Colloids Surf B Biointerfaces. 2025;255:114954. PubMed Abstract available
SAKA M, Teramoto Y, Haga H Immunohistochemistry scoring for human epidermal growth factor receptor 2 can be
used to predict pathological response to cisplatin-based neoadjuvant chemotherapy
in a subset of immunohistochemically subtyped muscle-invasive bladder cancer.
Virchows Arch. 2025 Jul 24. doi: 10.1007/s00428-025-04196. PubMed Abstract available
CHEN Y, Sun Y, Liu X Identification of lactylation-associated immune and metabolic regulators in
bladder cancer via integrated bulk and single-cell transcriptomics.
Front Immunol. 2025;16:1604758. PubMed Abstract available
KLEIN BY, Gofrit ON, Greenblatt CL Testing Protein Stress Signals in Peripheral Immunocytes Under the Same Treatment
Capable of Decreasing the Incidence of Alzheimer's Disease in Bladder Cancer
Patients.
Curr Issues Mol Biol. 2025;47:392. PubMed Abstract available
TANG X, Liu J, Zhao Q, Cao Y, et al TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in
Bladder Cancer Cells.
Curr Issues Mol Biol. 2025;47:369. PubMed Abstract available
OYLER HJ, Bruton LG, Maher AJ, Yu DA, et al Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects.
Curr Issues Mol Biol. 2025;47:278. PubMed Abstract available
CROCETTO F, Amicuzi U, Musone M, Magliocchetti M, et al Liquid Biopsy: Current advancements in clinical practice for bladder cancer.
J Liq Biopsy. 2025;9:100310. PubMed Abstract available
SHAH KA, Shah SR, Khan WA, Nisar S, et al Comparison of Intravesical Bacillus Calmette-Guerin (BCG) and Mitomycin C for the
Treatment of Non-Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e86524. PubMed Abstract available
TANG X, Yu T, Tong H, Wu Y, et al Advancements in bladder cancer immunotherapy: a focus on intravesical approaches.
Front Pharmacol. 2025;16:1578146. PubMed Abstract available
SINGH D, Mukherjee S Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer.
J Biochem Mol Toxicol. 2025;39:e70403. PubMed Abstract available
ZHOU Y, Zhang H, Yan H, Han P, et al Immune Landscape and Prognostic Significance of Gene Expression Profiles in
Bladder Cancer: Insights from Immune Cell Infiltration and Risk Modeling.
Iran J Allergy Asthma Immunol. 2025;24:519-532. PubMed Abstract available
CAI H, Xue P, Liu S, Ma Y, et al CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by
modulating cholesterol metabolism in bladder cancer.
J Nanobiotechnology. 2025;23:534. PubMed
SHENG Z, Liu J, Wang M, Chen X, et al Exploring bladder cancer through urinary microbiota: innovative "urinetypes"
classification and establishment of a diagnostic model.
J Transl Med. 2025;23:809. PubMed Abstract available
HAN X, Shi X, Ma T, Gao K, et al Development and preliminary verification of the scale of care needs of family
caregivers of patients with bladder cancer undergoing urostomy.
Sci Rep. 2025;15:26588. PubMed Abstract available
LEO P, Nezami BG, Akgul M, Tokuyama N, et al Computational Morphological Assessment of Bladder Cancer Tissue Is Prognostic of
Recurrence and Overall Survival Following Transurethral Resection.
JCO Clin Cancer Inform. 2025;9:e2400304. PubMed Abstract available
MEKALA V, Lin Y, Wang X, Chowdhury N, et al Integrative Analysis Reveals the Prognostic Effects of Epigenetic Regulators in
Bladder Cancer.
Cancer Med. 2025;14:e71057. PubMed Abstract available
LIU J, Qu Y, Xu X, Ye Z, et al A urine detection chip for the analysis of urinary cells and extracellular
vesicles for bladder cancer screening.
Lab Chip. 2025 Jul 22. doi: 10.1039/d5lc00511. PubMed Abstract available
GHASROLDASHT MM, Agarwal PK The role of exosomes in bladder cancer immunotherapy.
J Natl Cancer Cent. 2025;5:252-266. PubMed Abstract available
LIU W, Guo Y, Gong B, Fu X, et al Extracellular volume fraction quantification by equilibrium contrast-enhanced CT
via automated segmentation predicts survival outcomes in bladder cancer: a
propensity score-matched study.
Ann Med. 2025;57:2534856. PubMed Abstract available
YAN B, Liu Y, Li Y, Zheng J, et al Intracorporeal versus extracorporeal urinary diversion during robotic radical
cystectomy: outcomes from a large single-institutional study.
BMC Urol. 2025;25:179. PubMed Abstract available
SHORE ND, Powles TB, Bedke J, Galsky MD, et al Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle
invasive bladder cancer: the randomized phase 3 CREST trial.
Nat Med. 2025 Jul 21. doi: 10.1038/s41591-025-03894. PubMed
SAITO R, Taoka R, Miki J, Fukuokaya W, et al Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for
residual extravesical disease in muscle-invasive bladder cancer: insights from a
nationwide cohort.
Int J Clin Oncol. 2025 Jul 21. doi: 10.1007/s10147-025-02833. PubMed Abstract available
DRIGEARD DESGARNIER MC, Monshaugen I, Ougland R, Klungland A, et al The 6-methyladenine erasers ALKBH5 and FTO influence chemotherapy efficiency in
bladder cancer cell lines.
Ann Transl Med. 2025;13:26. PubMed Abstract available
HUANG W, Sun X, Liang Y, Mixdorf JC, et al [(89)Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder
cancer.
Am J Nucl Med Mol Imaging. 2025;15:87-96. PubMed Abstract available
LIANG Z, An Y, He J, Zhu Z, et al Comprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and
Immunotherapeutic Target with Experimental Validation in Bladder Cancer.
Int J Gen Med. 2025;18:3881-3900. PubMed Abstract available
JAYANTH ST, Debnath A, Gowri M, George AJP, et al Utilization of Neoaduvant Chemotherapy and Oncological Outcomes in Patients
Undergoing Radical Cystectomy for Variant Histology Versus Pure Urothelial
Bladder Cancer - A Retrospective Comparative Cohort Study.
Indian J Surg Oncol. 2025;16:753-761. PubMed Abstract available
SHEN J, Liu X, Li C, Hong L, et al Immune-related genes can accurately predict survival in bladder cancer: a
retrospective study via two independent immunotherapy cohorts.
Transl Androl Urol. 2025;14:1661-1678. PubMed Abstract available
DONG Y, Chen YA, Yu PZ, Liu Q, et al Leveraging hypoxia-related genes signature for predicting the prognosis of
bladder cancer.
Transl Androl Urol. 2025;14:1701-1722. PubMed Abstract available
HE Y, Dai F, Wang Z, Zhang S, et al Integrated single-cell genomics, transcriptomics, and pathomics to identify
potential biomarkers in muscle-invasive bladder cancer.
Transl Androl Urol. 2025;14:1610-1630. PubMed Abstract available
SIDIQI G, Stauch H, Johansson M, Alamdari F, et al Does neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder
cancer obliterate survival differences between genders?
Transl Androl Urol. 2025;14:1589-1600. PubMed Abstract available
DANIEL L, Ndiaye KS, Giguere H, Custeau LJ, et al Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder
cancer in preclinical and translational models.
Mol Ther Oncol. 2025;33:201016. PubMed Abstract available
Erratum: MT-12 inhibits the growth and metastasis of bladder cancer cells via
suppressing tumor angiogenesis in vivo and in vitro.
Transl Cancer Res. 2025;14:3874-3876. PubMed Abstract available
SHOLAN R, Aliyev R, Karimov S, Musayev J, et al Single-surgeon outcomes of open radical cystectomy for muscle-invasive bladder
cancer: Experience from a tertiary center in Azerbaijan.
Surg Pract Sci. 2025;22:100296. PubMed Abstract available
VAN JAARSVELD N, John J Non-muscle invasive bladder cancer in a pregnant patient.
Urol Case Rep. 2025;62:103119. PubMed Abstract available
FU S, Tao Y, Wu S, Gong Y, et al Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro
and in vivo.
FEBS Open Bio. 2025 Jul 21. doi: 10.1002/2211-5463.70089. PubMed Abstract available
MA T, Ma J, Wang Y, Kui X, et al Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine
resistance by downregulating S100A2 expression.
Biochem Pharmacol. 2025;241:117182. PubMed Abstract available
AKKOC Y, Sulhan H, Akgollu E, Cift A, et al The effect of HOTAIR gene variants on the development of bladder cancer and its
clinicopathological characteristics in a Caucasian population.
Cancer Genet. 2025;296-297:145-149. PubMed Abstract available
LI P, Yao S, Qi W, Liu H, et al Identification of FADS2 as a Contributor of Ferroptosis Escape in Bladder Cancer.
J Cell Mol Med. 2025;29:e70710. PubMed Abstract available
FUKUSHIMA T, Numakura K, Shinohara M, Kawashima Y, et al Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced
urothelial carcinoma.
Sci Rep. 2025;15:26127. PubMed Abstract available
KE C, Wan J, Wang G, Hu Z, et al Risk factors and therapeutic significance of HER2 overexpression in urothelial
carcinoma.
Pathol Res Pract. 2025;272:156079. PubMed Abstract available
ZHANG X, Wang S, Wang M, Wang L, et al Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder
Urothelial Carcinoma: A Prospective Diagnostic Model Validation.
Acad Radiol. 2025;32:4631-4641. PubMed Abstract available
UTOO BT, Agbo CA, Iorfa MS, Ukaonu SC, et al Calcified and Impacted Cervical Fibroid in a Young Female in a Low-resource
Setting Mistaken for Bladder Mass: Case Report and Literature Review.
Ann Afr Med. 2025;24:699-703. PubMed Abstract available
RYAN PC, Sugrue DD, O'Connell C, Salloum A, et al Improving the quality of transurethral resection of bladder tumour (TURBT)
operative notes following the European Association of Urology guidelines.
Ir J Med Sci. 2025;194:847-851. PubMed Abstract available
KLUMPER N, Kalogirou C, Eckstein M [Muscle-invasive and metastatic urothelial carcinoma from a pathological point of
view].
Aktuelle Urol. 2025;56:344-348. PubMed Abstract available
VON DEIMLING M, Furrer M, Bianchi A, Pichler R, et al Impact of timing of computed tomography staging and patient factors on the
detection of 'true' cN+ bladder cancer.
BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851. PubMed Abstract available
DE ANGELIS M, Scilipoti P, Santangelo A, Longoni M, et al The impact of histopathological evaluation at transurethral resection of bladder
tumour on survival in radical cystectomy candidates.
BJU Int. 2025;136:336-343. PubMed Abstract available
BEN-DAVID R, Pellegrino F, Mehrazin R, Thomas J, et al Immunotherapy-based neoadjuvant treatment and complication rates after radical
cystectomy.
BJU Int. 2025;136:321-328. PubMed Abstract available
HOF J, Vermeulen S, Richters A Biased associations between number of BCG instillations and outcome in
non-muscle-invasive bladder cancer.
BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866. PubMed
NIERENGARTEN MB FDA approves durvalumab for perioperative immunotherapy for patients with
muscle-invasive bladder cancer: In a prespecified analysis, the trial
demonstrated a statistically significant improvement in event-free survival and
overall survival.
Cancer. 2025;131:e35912. PubMed
LAZAROVICH A, Sweis RF The current and future role of systemic therapy in non-muscle-invasive bladder
cancer.
Cancer. 2025;131:e35966. PubMed Abstract available
DE JONG JJ, Reike MJ, Lotan Y, Seiler R, et al Molecular characterization of residual muscle-invasive bladder cancer identifies
a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant
therapy.
Clin Cancer Res. 2025 Jul 15. doi: 10.1158/1078-0432.CCR-24-3726. PubMed Abstract available
ULERI A, Katzendorn O, Khene ZE, Xylinas E, et al Novel intravesical delivery systems for nonmuscle invasive bladder cancer.
Curr Opin Urol. 2025 Jul 17. doi: 10.1097/MOU.0000000000001326. PubMed Abstract available
ZAURITO P, Scilipoti P, Montorsi F, Briganti A, et al Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle
invasive bladder cancer.
Curr Opin Urol. 2025 Jul 15. doi: 10.1097/MOU.0000000000001324. PubMed Abstract available
ARTILES MEDINA A, Subiela JD, Pichler R, Guerrero-Ramos F, et al Traditional and next-generation bacillus Calmette-Guerin based treatment
strategies for bacillus Calmette-Guerin unresponsive non-muscle-invasive bladder
cancer in the era of emerging therapies.
Curr Opin Urol. 2025 Jul 14. doi: 10.1097/MOU.0000000000001319. PubMed Abstract available
ANKER JF, Yu M, Galsky MD Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant
Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer
Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
Eur Urol. 2025 Jul 1:S0302-2838(25)00342-2. doi: 10.1016/j.eururo.2025. PubMed
BEEREN I, Kiebach J, Hof JP, Buffart LM, et al Physical activity and risks of recurrence and progression among patients with
non-muscle invasive bladder cancer.
Int J Cancer. 2025 Jun 30. doi: 10.1002/ijc.70030. PubMed Abstract available
KIMURA T, Inoue S, Sano T, Zennami K, et al Recent Advances and Future Directions in Bladder Preservation Therapy for
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70164. PubMed Abstract available
MINATO A, Takaba T, Higashijima K, Nagata Y, et al Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder
Cancer.
Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70119. PubMed
JI J, Guan F, Sun L, Zhang G, et al Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and
Meta-Analysis.
Int J Urol. 2025 Jul 9. doi: 10.1111/iju.70176. PubMed Abstract available
MARUYAMA Y, Sadahira T, Sekito T, Iwasaki Y, et al Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous
Thromboembolism After Robot-Assisted Radical Cystectomy.
Int J Urol. 2025;32:839-847. PubMed Abstract available
MANTICA G, Calarco A, Leonardi R Artificial intelligence for rare bladder cancer variants: a new hope for
detection?
Int Urol Nephrol. 2025 Jul 4. doi: 10.1007/s11255-025-04647. PubMed
LI JKM, Wang L, Tse RTH, Leung CH, et al A cross-sectional study on the effects of intravesical BCG on urinary microbiota
in bladder cancer patients.
Int Urol Nephrol. 2025 Jun 30. doi: 10.1007/s11255-025-04607. PubMed Abstract available
IOSSA V, Olivieri A, Buonopane R, Di Girolamo A, et al Assessment of quality of life in patients undergoing hyperthermic intravesical
chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).
Int Urol Nephrol. 2025;57:2415-2423. PubMed Abstract available
HUSSEIN AA, Mahmood AW, Ahmad A, Houenstein H, et al Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections after
Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial.
J Urol. 2025 Apr 25:101097JU0000000000004586. doi: 10.1097/JU.0000000000004586. PubMed Abstract available
LUO Y, Zeng Y, Liu Y, Liu S, et al ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via
53BP1 acetylation.
Oncogene. 2025 Jul 1. doi: 10.1038/s41388-025-03474. PubMed Abstract available
MACINTYRE I, Kool R, Marcq G, Kulkarni GS, et al Effect of Sex Differences on Cancer Outcomes after Chemo-Radiation for
Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study.
Urology. 2025 Jun 28:S0090-4295(25)00636-3. doi: 10.1016/j.urology.2025. PubMed Abstract available
WANG B, Gong Z, Su P, Zhen G, et al Multi-machine learning model based on radiomics features to predict prognosis of
muscle-invasive bladder cancer.
BMC Cancer. 2025;25:1116. PubMed Abstract available
HUANG L, Yan D, Ruan H, Lin Q, et al BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
BMC Cancer. 2025;25:1057. PubMed Abstract available
LI J, Liang J, Xu Y, Tan W, et al Droplet digital PCR assay for precise determination of FRS2 gene copy number in
bladder cancer.
BMC Cancer. 2025;25:1211. PubMed Abstract available
